[Clinical observations on the treatment of obese patients with dexfenfluramine].
In a 12-months double-blind study 42 obese patients (5 males, 37 females) were treated either with d-fenfluramine (30 mg daily) or with placebo plus low-calorie diet (1500-1200 kcal daily). Evaluation of treatment efficacy was based on evolution of the initial cohort, weight loss, number of subjects completing treatment, tolerability and events leading to dropout. Patients receiving d-fenfluramine had statistically significant greater weight loss than the placebo group; 30 mg daily proved to be an effective and well tolerated dose of d-fenfluramine with the best long-term activity/acceptability ratio.
Cairella
M
M
Servizio di Dietologia, Università degli Studi di Roma La Sapienza.
Pisculli
M
M
Petraroli
A R
AR
Riganelli
S
S
Saracino
A
A
Siani
V
V
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D005277:Fenfluramine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy*; D010919:Placebos; D016032:Randomized Controlled Trials as Topic
D010919:Placebos; D005277:Fenfluramine
Osservazioni cliniche sul trattamento di pazienti obesi con dexfenfluramina.